AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / CHEMICALS & ALLIED PRODUCTS
Innospec Inc.
XNAS · usd
SIC 2800 · CHEMICALS & ALLIED PRODUCTS
FIGI BBG001S8RTD2
98.64▼ 0.03 (-0.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
98.67
Day's Range
97.12 – 98.91
52-Week Range
65.50 – 100.48
Volume
113.2K
Avg Volume
235.3K
Share Statistics
Shares Outstanding
Employees
2,450
Exchange
XNAS
Listed
1998-05-13
Share count as of July 31, 2026

Innospec Inc. (IOSP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Innospec Inc. (IOSP)
What is Innospec Inc.'s Market Cap?
Innospec Inc.'s Market Cap is $2.4B, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s Trailing P/E?
Innospec Inc.'s Trailing P/E is 20.1×, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s Price / Sales?
Innospec Inc.'s Price / Sales is 1.3×, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s Revenue (TTM)?
Innospec Inc.'s Revenue (TTM) is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s Net Income (TTM)?
Innospec Inc.'s Net Income (TTM) is $121.1M, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s EBITDA?
Innospec Inc.'s EBITDA is $170.4M, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s Diluted EPS (TTM)?
Innospec Inc.'s Diluted EPS (TTM) is 4.92, based on as-reported figures from SEC (XBRL) filings.
What is Innospec Inc.'s EBITDA Margin?
Innospec Inc.'s EBITDA Margin is 9.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IOSPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net sales
YoY growth+11.8%+2.8%-2.4%-0.3%
Cost of goods sold
Gross profit
% of revenue28.1%27.3%28.0%26.4%
Operating expenses:
Selling, general and administrative
Research and development
Adjustment to fair value of contingent consideration
Profit on disposal of property, plant and equipment
Total operating expenses
% of revenue-20.1%-19.2%-17.7%-25.1%
Operating income
% of revenue8.1%8.1%10.3%1.3%
Other income/(expense), net
Interest income, net
Income before income tax expense
Income tax expense
Net income
% of revenue6.3%6.8%10.4%2.9%
Net income attributable to non-controlling interests——
Net income attributable to Innospec——
% of revenue6.3%6.7%——
Basic
Diluted